Treatment with αCBSF partially prevented neuronal loss in the neocortex region compared with AgBSF treatment, as demonstrated by NeuN antibody immunohistochemical staining, thus indicating that αCBSF may confer neuroprotective ability for AD brain (Fig. 10A and B). This evidence concerns the gene RBFOX3 and Alzheimer disease.